ReviewJournal of nanobiotechnology2022
An overview on nanoparticle-based strategies to fight viral infections with a focus on COVID-19.
Review in Journal of nanobiotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 89 citations in OpenAlex.
- Smart nanoparticle vaccines integrate nanotechnology artificial intelligence and immunoengineering for precision immunization.Discover nano · 2026Review
- Silver-Zinc oxide nanocomposites: a green approach to mitigate herpes simplex virus type 1 challenges.Scientific reports · 2026Article
- Nanotechnology in COVID-19 prevention, diagnosis, and treatment: a comprehensive review.Discover nano · 2025Review
- The Elicitation of an Antigen-Specific Antibody Immune Response Using a Nanoparticulate Adjuvant Derived fromMolecules (Basel, Switzerland) · 2025Article
- Replacing protruding domains of MrNV virus-like particles with sialic acid binding domains enhances binding to SARS-CoV-2 susceptible cells and reduces pseudovirus infection.Scientific reports · 2025Article
- Recent Advances in mRNA-Based Vaccines Against Several Hepatitis Viruses.Biological procedures online · 2025Review
- Investigating the relationship between cycle threshold of SARS-CoV-2 RT-PCR, clinical features, and laboratory data in hospitalized COVID-19 patients in Semnan, Iran.Frontiers in cellular and infection microbiology · 2025Article
- Mesenchymal stem cells and their extracellular vesicle therapy for neurological disorders: traumatic brain injury and beyond.Frontiers in neurology · 2025Review
- Preparation and characterization of micellar nanoparticles using crude saponins from five Congolese plant species.Pharmaceutical science advances · 2024Article
- Recent Advances in Crimean-Congo Hemorrhagic Fever Virus Detection, Treatment, and Vaccination: Overview of Current Status and Challenges.Biological procedures online · 2024Review
- Potential Use of the Cholesterol Transfer Inhibitor U18666A as a Potent Research Tool for the Study of Cholesterol Mechanisms in Neurodegenerative Disorders.Molecular neurobiology · 2024Review
- Immunomodulatory effects of cannabinoids against viral infections: a review of its potential use in SARS-CoV2 infection.Virusdisease · 2024Review
- The potential use of therapeutics and prophylactic mRNA vaccines in human papillomavirus (HPV).Virology journal · 2024Review
- An overview on mRNA-based vaccines to prevent monkeypox infection.Journal of nanobiotechnology · 2024Review
- Nanotechnology's frontier in combatting infectious and inflammatory diseases: prevention and treatment.Signal transduction and targeted therapy · 2024Review
- Drug Nanocrystals: A Delivery Channel for Antiviral Therapies.AAPS PharmSciTech · 2024Review
- Maltodextrin-Nanoparticles as a Delivery System for Nasal Vaccines: A Review Article.Pharmaceutics · 2024Review
- Fabrication of magnetic niosomal platform for delivery of resveratrol: potential anticancer activity against human pancreatic cancer Capan-1 cell.Cancer cell international · 2024Article
- Spotlight on therapeutic efficiency of green synthesis metals and their oxide nanoparticles in periodontitis.Journal of nanobiotechnology · 2024Review
- An overview of the role of Niemann-pick C1 (NPC1) in viral infections and inhibition of viral infections through NPC1 inhibitor.Cell communication and signaling : CCS · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 9 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to COVID-19 and has become a pandemic worldwide with mortality of millions. Nanotechnology can be used to deliver antiviral medicines or other types of viral reproduction-inhibiting medications. At various steps of viral infection, nanotechnology could suggest practical solutions for usage in the fight against viral infection. Nanotechnology-based approaches can help in the fight against SARS-CoV-2 infection. Nanoparticles can play an essential role in progressing SARS-CoV-2 treatment and vaccine production in efficacy and safety. Nanocarriers have increased the speed of vaccine development and the efficiency of vaccines. As a result, the increased investigation into nanoparticles as nano-delivery systems and nanotherapeutics in viral infection, and the development of new and effective methods are essential for inhibiting SARS-CoV-2 infection. In this article, we compare the attributes of several nanoparticles and evaluate their capability to create novel vaccines and treatment methods against different types of viral diseases, especially the SARS-CoV-2 disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.